Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial

Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.